50S ribosomal subunit Inhibitors
3 drugsAbout 50S ribosomal subunit
The 50S ribosomal subunit is a critical component of bacterial ribosomes, essential for protein synthesis. Disrupting its function inhibits bacterial growth, making it a well-established antibacterial target.
Targeting the 50S ribosomal subunit is a proven antibacterial strategy, though no genetic evidence directly links subunit variations to disease susceptibility.
Three small molecule drugs, including ERYTHROMYCIN LACTOBIONATE, ERYTHROCIN, and ERY-TAB, target this subunit. These drugs are marketed by GLAND, Pfizer and PHARMOBEDIENT.
Top 50S ribosomal subunit Drugs
The competitive landscape includes three companies with approved drugs: GLAND, Pfizer, and PHARMOBEDIENT.
Limited number of players suggests moderate barriers to entry, but also less competition.
50S ribosomal subunit Drug Modality Landscape
Modalities
Routes of Administration
50S ribosomal subunit is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like peptides or biologics to differentiate from existing therapies.
50S ribosomal subunit Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on 50S ribosomal subunit. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 16 | 15 | 0 | 1 | 100% |
| Phase 2 | 7 | 5 | 2 | 0 | 71% |
| Phase 3 | 4 | 1 | 2 | 1 | 33% |
| Phase 4 | 5 | 2 | 0 | 3 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
50S ribosomal subunit Drug Approval Timeline (1964 - 1982)
The first drug was approved in 1964 (ERYTHROCIN), and the most recent in 1989 (ERYTHROMYCIN LACTOBIONATE).
The long gap since the last approval indicates potential saturation or challenges in developing new drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 30 (15 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on 50S ribosomal subunit. A trial counts if an approved drug acting on 50S ribosomal subunit is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.